Roferon-A interferon alfa-2a regulatory update

The FDA's Oncologic Drugs Advisory Committee (ODAC) voted 7-0 against recommending approval of Roche's Roferon-A to treat Stage II malignant melanoma. The product is marketed to treat chronic myelogen...